Skip to main content
Top
Published in: Tumor Biology 9/2016

01-09-2016 | Original Article

Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers

Authors: Kristyna Hudcova, Martina Raudenska, Jaromir Gumulec, Hana Binkova, Zuzana Horakova, Rom Kostrica, Petr Babula, Vojtech Adam, Michal Masarik

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

Altered expression of microRNAs (miRNAs) has been shown in many types of malignancies including the head and neck squamous cell carcinoma (HNSCC). Although there are many new and innovative approaches in the treatment of HNSCC, a clear marker of this disease is still missing. Three candidate miRNAs (miR-29c-3p, miR-200b-5p and miR-375-3p) were studied in connection with HNSCC using quantitative real-time PCR expression levels in 42 tissue samples of HNSCC patients and histologically normal tumour-adjacent tissue samples of these patients. Primary HNSCC carcinoma tissues can be distinguished from histologically normal-matched noncancerous tumour-adjacent tissues based on hsa-miR-375-3p expression (sensitivity 87.5 %, specificity 65 %). Additionally, a significant decrease of hsa-miR-200b-5p expression was revealed in tumour-adjacent tissue samples of patients with node positivity. Lower expression of hsa-miR-200b-5p and hsa-miR-29c-3p in HNSCC tumour tissue was associated with higher tumour grade. Consequently, survival analysis was performed. Lower expression of hsa-miR-29c-3p in tumour-adjacent tissue was associated with worse overall and disease-specific survivals. Lower expression of miR-29c-3p in tumourous tissue was associated with worse relapse-free survival. hsa-miR-375-3p seems to be a relatively promising diagnostic marker in HNSCC but is not suitable for prognosis of patients. Furthermore, this study highlighted the importance of histologically normal tumour-adjacent tissue in HNSCC progress (significant decrease of hsa-miR-200b-5p expression in tumour-adjacent tissue of patients with node positivity and low expression of hsa-miR-29c-3p in HNSCC tumour-adjacent tissue associated with worse prognosis).
Literature
4.
go back to reference Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Research International. 2015:125094. doi:10.1155/2015/125094. Lan H, Lu H, Wang X, Jin H. MicroRNAs as potential biomarkers in cancer: opportunities and challenges. Biomed Research International. 2015:125094. doi:10.​1155/​2015/​125094.
7.
go back to reference Schmitt MJ, Margue C, Behrmann I, Kreis S. miRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med. 2013;13(4):572–85.CrossRefPubMed Schmitt MJ, Margue C, Behrmann I, Kreis S. miRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med. 2013;13(4):572–85.CrossRefPubMed
8.
go back to reference Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 2014;33(20):2557–67. doi:10.1038/onc.2013.216.CrossRefPubMed Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 2014;33(20):2557–67. doi:10.​1038/​onc.​2013.​216.CrossRefPubMed
10.
go back to reference Zou YK, Li JW, Chen ZY, Li XW, Zheng SG, Yi D, et al. miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients. Carcinogenesis. 2015;36(6):676–84. doi:10.1093/carcin/bgv027.CrossRefPubMed Zou YK, Li JW, Chen ZY, Li XW, Zheng SG, Yi D, et al. miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients. Carcinogenesis. 2015;36(6):676–84. doi:10.​1093/​carcin/​bgv027.CrossRefPubMed
11.
13.
go back to reference Diaz-Martin J, Diaz-Lopez A, Moreno-Bueno G, Castilla MA, Rosa-Rosa JM, Cano A, et al. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol. 2014;232(3):319–29. doi:10.1002/path.4289.CrossRefPubMed Diaz-Martin J, Diaz-Lopez A, Moreno-Bueno G, Castilla MA, Rosa-Rosa JM, Cano A, et al. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol. 2014;232(3):319–29. doi:10.​1002/​path.​4289.CrossRefPubMed
14.
27.
go back to reference Tang X, Hou Y, Yang G, Wang X, Tang S, Du YE, et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ. 2016;23(1):132–45. doi:10.1038/cdd.2015.78.CrossRefPubMed Tang X, Hou Y, Yang G, Wang X, Tang S, Du YE, et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ. 2016;23(1):132–45. doi:10.​1038/​cdd.​2015.​78.CrossRefPubMed
32.
go back to reference Matamala N, Teresa Vargas M, Gonzalez-Campora R, Minambres R, Ignacio Arias J, Menendez P, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015;61(8):1098–106. doi:10.1373/clinchem.2015.238691.CrossRefPubMed Matamala N, Teresa Vargas M, Gonzalez-Campora R, Minambres R, Ignacio Arias J, Menendez P, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015;61(8):1098–106. doi:10.​1373/​clinchem.​2015.​238691.CrossRefPubMed
Metadata
Title
Expression profiles of miR-29c, miR-200b and miR-375 in tumour and tumour-adjacent tissues of head and neck cancers
Authors
Kristyna Hudcova
Martina Raudenska
Jaromir Gumulec
Hana Binkova
Zuzana Horakova
Rom Kostrica
Petr Babula
Vojtech Adam
Michal Masarik
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5147-2

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine